Immunic, Inc. Announces Participation in Upcoming Investor and Scientific Conferences

NEW YORK, March 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a leader in the development of therapies for inflammatory and autoimmune diseases, has released its schedule for participation in various investor and scientific conferences throughout March. The company aims to engage with investors and present its research findings across several important events.

At the Leerink Partners Global Biopharma Conference from March 11-13 in Miami, FL, Immunic's CEO, Daniel Vitt, Ph.D., alongside Jessica Breu, Vice President of Investor Relations and Communications, will engage in one-on-one meetings with investors. Following this, the company plans to showcase two of its abstracts through poster presentations at the Frontiers in Medicinal Chemistry conference, held in Munich, Germany, from March 17-20. These presentations will be available on Immunic's website.

Moreover, the 33rd Annual Meeting of the Society for Virology in Vienna, Austria, from March 25-28, will feature Immunic's research in poster and oral presentations. The focus will be on the development of broad-spectrum antivirals and the characterization of Mpox Virus genomes.

Immunic's active participation in these events underscores its commitment to advancing the understanding and treatment of chronic inflammatory and autoimmune conditions through its innovative therapeutic approaches.